CUTISS AG has announced the start of production at its new on-site manufacturing facility in Schlieren. According to a press release, the startup specializing in personalized skin grafts and skin tissue therapy will now manufacture its own denovoSkin product at the facility in the Bio-Technopark Schlieren-Zurich. This follows a successful transfer of technology from Wyss Zurich Translational Center to CUTISS in Schlieren.
In December, CUTISS received the certification of compliance for Good Manufacturing Practices (GMP) and Good Distribution Practices (GDP) from the regulator Swissmedic, the Swiss Agency for Therapeutic Products, for its manufacturing facility in Schlieren, Zurich.
Kathi Mujynya, Chief Operating Officer at CUTISS, said the opening of its own facility represents a critical milestone. “It centralizes our activities around the manufacturing of denovoSkin, increases our production capacities, and enables us to scale up the manufacturing process and take our automation program to the next level.”
The state-of-the-art facility, located at the company’s headquarters at the Biotechnopark in Zurich-Schlieren, covers a surface area of 150sqm and is comprised of several laboratories including a biobank and a histology lab. The announcement coincides with the five-year anniversary of the startup, which was established in March 2017 as a spin-off from the University of Zurich (UZH).